ESMO Asia 2023 | Will enfortumab vedotin and pembrolizumab be the new SOC in urothelial cancer?

Enrique Grande, MD, PhD, MD Anderson Cancer Centre Madrid, Madrid, Spain, discusses the implications of the findings from the EV-302 trial (NCT04223856) of enfortumab vedotin, an antibody-drug conjugate (ADC), and pembrolizumab in patients with locally advanced or metastatic urothelial cancer. The investigational regimen was found to be superior to the current standard of care, which typically consists of a cisplatin or carboplatin-based therapy in terms of medial overall survival. Consequently, enfortumab vedotin and pembrolizumab is seen as practice-changing. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.